spotlight on hiv

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Sarah Bauerle Bass, PhD, MPH, FSBM

Although the rate of new HIV diagnoses in the United States is steadily declining, people in prisons are still disproportionately living with the virus, which is why researchers at Temple University are now developing an app aimed at improving HIV prevention and substance use treatment access for incarcerated women in Philadelphia. To learn more about this research, Dr. Mary Katherine Cheeley is joined by Dr. Sarah Bauerle Bass, Associate Professor of Social and Behavioral Sciences and the Director of Risk Communication Laboratory at Temple University.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kamel Khalili, PhD

Scientists at Temple University’s Lewis Katz School of Medicine have identified a novel gene-editing strategy aimed at eliminating HIV-1 infection with no adverse effects on cell mortality. Find out how this recent discovery could get us one step closer to a cure for HIV with Dr. Charles Turck and Dr. Kamel Khalili, the Laura H. Carnell Professor in the Department of Neuroscience and Chair of the Department of Microbiology, Immunology & Inflammation.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kamel Khalili, PhD

Scientists at Temple University’s Lewis Katz School of Medicine have identified a novel gene-editing strategy aimed at eliminating HIV-1 infection with no adverse effects on cell mortality. Find out how this recent discovery could get us one step closer to a cure for HIV with Dr. Charles Turck and Dr. Kamel Khalili, the Laura H. Carnell Professor in the Department of Neuroscience and Chair of the Department of Microbiology, Immunology & Inflammation.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kamel Khalili, PhD

Scientists at Temple University’s Lewis Katz School of Medicine have identified a novel gene-editing strategy aimed at eliminating HIV-1 infection with no adverse effects on cell mortality. Find out how this recent discovery could get us one step closer to a cure for HIV with Dr. Charles Turck and Dr. Kamel Khalili, the Laura H. Carnell Professor in the Department of Neuroscience and Chair of the Department of Microbiology, Immunology & Inflammation.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kamel Khalili, PhD

Scientists at Temple University’s Lewis Katz School of Medicine have identified a novel gene-editing strategy aimed at eliminating HIV-1 infection with no adverse effects on cell mortality. Find out how this recent discovery could get us one step closer to a cure for HIV with Dr. Charles Turck and Dr. Kamel Khalili, the Laura H. Carnell Professor in the Department of Neuroscience and Chair of the Department of Microbiology, Immunology & Inflammation.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kamel Khalili, PhD

Scientists at Temple University’s Lewis Katz School of Medicine have identified a novel gene-editing strategy aimed at eliminating HIV-1 infection with no adverse effects on cell mortality. Find out how this recent discovery could get us one step closer to a cure for HIV with Dr. Charles Turck and Dr. Kamel Khalili, the Laura H. Carnell Professor in the Department of Neuroscience and Chair of the Department of Microbiology, Immunology & Inflammation.

Host: Jerome Lisk, MD
Guest: Santosh Kumar, PhD

In an effort to examine the correlation between HIV-induced aging and Alzheimer’s disease in the United States population, a team of researchers at the University of Tennessee Health Science Center are working to develop a novel drug delivery system. To learn more, Dr. Jerome Lisk is joined by Dr. Santosh Kumar to discuss his current research and the effects it could have on future treatment approaches for HIV-induced aging and Alzheimer’s disease. Dr. Kumar is a Professor in the Department of Pharmaceutical Science at the University of Tennessee.

Host: Jerome Lisk, MD
Guest: Santosh Kumar, PhD

In an effort to examine the correlation between HIV-induced aging and Alzheimer’s disease in the United States population, a team of researchers at the University of Tennessee Health Science Center are working to develop a novel drug delivery system. To learn more, Dr. Jerome Lisk is joined by Dr. Santosh Kumar to discuss his current research and the effects it could have on future treatment approaches for HIV-induced aging and Alzheimer’s disease. Dr. Kumar is a Professor in the Department of Pharmaceutical Science at the University of Tennessee.

Host: Jerome Lisk, MD
Guest: Santosh Kumar, PhD

In an effort to examine the correlation between HIV-induced aging and Alzheimer’s disease in the United States population, a team of researchers at the University of Tennessee Health Science Center are working to develop a novel drug delivery system. To learn more, Dr. Jerome Lisk is joined by Dr. Santosh Kumar to discuss his current research and the effects it could have on future treatment approaches for HIV-induced aging and Alzheimer’s disease. Dr. Kumar is a Professor in the Department of Pharmaceutical Science at the University of Tennessee.

Host: Jerome Lisk, MD
Guest: Santosh Kumar, PhD

In an effort to examine the correlation between HIV-induced aging and Alzheimer’s disease in the United States population, a team of researchers at the University of Tennessee Health Science Center are working to develop a novel drug delivery system. To learn more, Dr. Jerome Lisk is joined by Dr. Santosh Kumar to discuss his current research and the effects it could have on future treatment approaches for HIV-induced aging and Alzheimer’s disease. Dr. Kumar is a Professor in the Department of Pharmaceutical Science at the University of Tennessee.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Steve Grinspoon, MD

Many studies over the last few years have shown that the risks of cardiovascular disease have increased between 50 to 100 percent among patients with HIV. So what steps need to be taken to help reduce this risk for our patients? Here to discuss what we need to know is Dr. Mary Katherine Cheeley and Dr. Steven Grinspoon, Professor of Medicine at Harvard Medical School and Chief of the Metabolism Unit at Massachusetts General Hospital.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Steve Grinspoon, MD

Many studies over the last few years have shown that the risks of cardiovascular disease have increased between 50 to 100 percent among patients with HIV. So what steps need to be taken to help reduce this risk for our patients? Here to discuss what we need to know is Dr. Mary Katherine Cheeley and Dr. Steven Grinspoon, Professor of Medicine at Harvard Medical School and Chief of the Metabolism Unit at Massachusetts General Hospital.

Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Steve Grinspoon, MD

Many studies over the last few years have shown that the risks of cardiovascular disease have increased between 50 to 100 percent among patients with HIV. So what steps need to be taken to help reduce this risk for our patients? Here to discuss what we need to know is Dr. Mary Katherine Cheeley and Dr. Steven Grinspoon, Professor of Medicine at Harvard Medical School and Chief of the Metabolism Unit at Massachusetts General Hospital.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew Clark, MD

Emerging treatment options have helped patients with HIV live longer, but the aging population faces its own unique challenges. To explore how we can combat these challenges—including the ongoing stigma around HIV—Dr. Charles Turck is joined by Dr. Andrew Clark, who is the Global Medical Lead at ViiV Healthcare.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew Clark, MD

Emerging treatment options have helped patients with HIV live longer, but the aging population faces its own unique challenges. To explore how we can combat these challenges—including the ongoing stigma around HIV—Dr. Charles Turck is joined by Dr. Andrew Clark, who is the Global Medical Lead at ViiV Healthcare.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew Clark, MD

Emerging treatment options have helped patients with HIV live longer, but the aging population faces its own unique challenges. To explore how we can combat these challenges—including the ongoing stigma around HIV—Dr. Charles Turck is joined by Dr. Andrew Clark, who is the Global Medical Lead at ViiV Healthcare.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew Clark, MD

Emerging treatment options have helped patients with HIV live longer, but the aging population faces its own unique challenges. To explore how we can combat these challenges—including the ongoing stigma around HIV—Dr. Charles Turck is joined by Dr. Andrew Clark, who is the Global Medical Lead at ViiV Healthcare.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Chris Beyrer, MD, MPH

Amid the ongoing COVID-19 pandemic, countries in Sub-Saharan Africa are also facing high rates of HIV and AIDS prevalence. But after the success of the mRNA COVID-19 vaccines, could an mRNA vaccine for HIV/AIDS be on the horizon? Here to explore emerging research and the potential role that mRNA technology might have in battling this global epidemic is Dr. Chris Beyrer, a Professor of Epidemiology at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Chris Beyrer, MD, MPH

Amid the ongoing COVID-19 pandemic, countries in Sub-Saharan Africa are also facing high rates of HIV and AIDS prevalence. But after the success of the mRNA COVID-19 vaccines, could an mRNA vaccine for HIV/AIDS be on the horizon? Here to explore emerging research and the potential role that mRNA technology might have in battling this global epidemic is Dr. Chris Beyrer, a Professor of Epidemiology at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Chris Beyrer, MD, MPH

Amid the ongoing COVID-19 pandemic, countries in Sub-Saharan Africa are also facing high rates of HIV and AIDS prevalence. But after the success of the mRNA COVID-19 vaccines, could an mRNA vaccine for HIV/AIDS be on the horizon? Here to explore emerging research and the potential role that mRNA technology might have in battling this global epidemic is Dr. Chris Beyrer, a Professor of Epidemiology at the Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland.